Rosuvastatin 20mg + Ezetimibe 10mg Tablet in PCD pharma franchise in Hyderabad

Rosuvastatin 20mg + Ezetimibe 10mg Tablet in pharmaceutical manufacturing company in Mumbai

Rosuvastatin 20mg + Ezetimibe 10mg Tablet in cholesterol care pharma franchise in Pune

Rosuvastatin 20mg + Ezetimibe 10mg Tablet in pharma suppliers in Delhi

Rosuvastatin 20mg + Ezetimibe 10mg Tablet in pharma export companies in Kolkata
Rosuvastatin 20mg + Ezetimibe 10mg Tablet in pharma franchise opportunities in Bengaluru

Home/Products /rosuvastatin-20-mg-ezetimibe-10-mg-tablet

Rosumore EZ 20 Tablet

Composition : Rosuvastatin 20 mg + Ezetimibe 10 mg tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹1/-

Rosuvastatin 20 mg + Ezetimibe 10 mg Tablet is a dual-action lipid-lowering formulation that combines a statin with a cholesterol absorption inhibitor. Rosuvastatin, an HMG-CoA reductase inhibitor, works by reducing cholesterol synthesis in the liver, while Ezetimibe selectively inhibits the absorption of cholesterol from the small intestine. Together, they provide a synergistic effect to effectively lower LDL cholesterol and total cholesterol levels, making it suitable for patients who require intensive lipid control or have not achieved goals with statin monotherapy. This combination supports cardiovascular risk reduction in patients with hyperlipidemia or mixed dyslipidemia.

Read More

About the Product

Rosuvastatin 20 mg + Ezetimibe 10 mg Tablet is a dual-action lipid-lowering formulation that combines a statin with a cholesterol absorption inhibitor. Rosuvastatin, an HMG-CoA reductase inhibitor, works by reducing cholesterol synthesis in the liver, while Ezetimibe selectively inhibits the absorption of cholesterol from the small intestine. Together, they provide a synergistic effect to effectively lower LDL cholesterol and total cholesterol levels, making it suitable for patients who require intensive lipid control or have not achieved goals with statin monotherapy. This combination supports cardiovascular risk reduction in patients with hyperlipidemia or mixed dyslipidemia.

Common side effects may include headache, muscle pain, fatigue, and abdominal discomfort. In rare cases, patients may experience liver enzyme elevation, rhabdomyolysis, or hypersensitivity reactions. Periodic monitoring of liver function and creatine kinase levels is advised, especially in patients with predisposing factors for myopathy.

Indicated for the treatment of primary hyperlipidemia or mixed dyslipidemia in adults as an adjunct to diet. It is particularly beneficial for patients requiring additional LDL cholesterol reduction when lifestyle modifications and statin therapy alone are insufficient. The combination is also used in the management of homozygous familial hypercholesterolemia and to lower the risk of cardiovascular events in high-risk patients.

To be used under the supervision of a registered medical practitioner. Not recommended in patients with active liver disease or unexplained persistent elevations in hepatic transaminases. Caution should be exercised in patients with renal impairment or those on other lipid-lowering agents. Avoid use during pregnancy and lactation.

Store at a temperature below 30°C, away from moisture and direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation